Revlimid Multiple Myeloma Trial Paused Due to Blood Clots
This article was originally published in The Pink Sheet Daily
Executive Summary
Celgene asserts that the Mayo Clinic study will resume within weeks, after the trial design is changed to require patients to receive aspirin prior to combo therapy of Revlimid/dexamethasone.
You may also be interested in...
Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis
Study finds that concurrent use of erythropoietin agents with Revlimid and dexamethasone should be minimized.
Celgene’s Revlimid In Multiple Myeloma Reviewed At ASCO For Risk Of Thrombosis
Study finds that concurrent use of erythropoietin agents with Revlimid and dexamethasone should be minimized.
Revlimid Approved With Safeguards Against Fetal Exposure
Education and prescribing safety program for Celgene’s Revlimid will restrict distribution and address risks of fetal exposure; the firm has ongoing studies to assess teratogenicity.